A5011110057- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Cardiac pacing and defibrillation studies
- Aortic Disease and Treatment Approaches
- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Takotsubo Cardiomyopathy and Associated Phenomena
- Coronary Interventions and Diagnostics
- Cardiovascular Issues in Pregnancy
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac tumors and thrombi
- Pericarditis and Cardiac Tamponade
- Advanced MRI Techniques and Applications
- Aortic Thrombus and Embolism
- Acute Myocardial Infarction Research
- Cardiomyopathy and Myosin Studies
- Nuclear Receptors and Signaling
- Cardiac and Coronary Surgery Techniques
- Lipoproteins and Cardiovascular Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Vascular Tumors and Angiosarcomas
- Cardiovascular and Diving-Related Complications
Morristown Medical Center
2015-2024
Atlantic Health System
2016-2024
Deutsches Herzzentrum München
2024
Essen University Hospital
2024
Thomas Jefferson University
2018
Cardiovascular Institute of the South
2016
Carnegie Hall
2016
Columbia University Irving Medical Center
2014
Columbia University
2013
Christiana Care Health System
2008-2010
The American College of Cardiology/American Heart Association guidelines recommend the assessment and grading severity aortic stenosis (AS) as mild, moderate, or severe, per echocardiogram, valve replacement (AVR) when AS is severe. authors sought to describe mortality rates across entire spectrum untreated from a contemporary, large, real-world database. We analyzed deidentified data set including 1,669,536 echocardiographic reports (1,085,850 patients) 24 U.S. hospitals (egnite Database,...
Abstract Aims Incomplete left atrial appendage occlusion (LAAO) due to peri-device leak (PDL) is a limitation of the therapy. The Amulet IDE trial largest randomized head-to-head comparing and Watchman 2.5 LAAO devices with fundamentally different designs. predictors mechanistic factors impacting differences in PDLs within are assessed current analysis. Methods results An independent core lab analysed all images for presence or absence severe PDL (>5 mm). incidence, factors, using...
Mitral transcatheter edge-to-edge repair (M-TEER) is a guideline-recommended treatment option for patients with severe symptomatic mitral regurgitation (MR). Outcomes the PASCAL system in post-market setting have not been established. The authors report 30-day and 1-year outcomes from MiCLASP (Transcatheter Repair of Regurgitation Edwards Transcatheter Valve System) European clinical follow-up study. Patients symptomatic, clinically significant MR were prospectively enrolled. primary safety...
Background: The American College of Cardiology/American Heart Association and Society Echocardiography guidelines recommend assessing several echocardiographic parameters when evaluating mitral regurgitation (MR) severity. These can be discordant, making the assessment MR challenging. degree to which severity are concordant is not well studied. Methods: We enrolled 159 patients in a prospective multicenter study. Eight were included this analysis: proximal isovelocity surface area...
Mitral valve transcatheter edge-to-edge repair (M-TEER) is an effective option for treatment of mitral regurgitation (MR). We previously reported favorable 2-year outcomes the PASCAL system.We report 3-year from multinational, prospective, single-arm CLASP study with analysis by functional MR (FMR) and degenerative (DMR).Patients core-lab determined ≥ 3+ were deemed candidates M-TEER local heart team. Major adverse events assessed independent clinical committee to 1 year sites thereafter....